Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Alexander A. Harris, MD1, Mark Korpics, MD2, Zohaib Sherwani, BS1, Ahmer Farooq, DO3, Kristin G. Baldea, MD3, Robert Flanigan, MD3, Matthew M. Harkenrider, MD3, Abhishek A. Solanki, MD1

1Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA, 2Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA, 3Department of Urology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA

Abstract

Purpose: High-dose-rate (HDR) brachytherapy is an effective method of treating localized prostate cancer. There are limited data on the relationship between implant interval and outcomes. This study aims to assess if the implant interval between HDR treatments has an impact on patient-reported health-related quality of life (QOL) and physician-rated toxicity in men treated for localized prostate cancer.

Material and methods: Patients were treated with HDR brachytherapy as monotherapy with 27 Gy in 2 fractions, given over two implants, performed 1-2 weeks apart. Patients were dichotomized into one-week and two-week cohorts. Patient-reported EPIC-26 genitourinary (GU), gastrointestinal (GI), and sexual QOL were assessed. Linear regression, chi-squared testing, and generalized linear mixed effect models were used to assess the differences in patient characteristics, patient-reported QOL, and physician-rated toxicity.

Results: Outcomes of 122 patients were analyzed. Median follow-up was 18 months. Patient-reported GU and GI QOL worsened after treatment with a return towards baseline over time, while patient-reported sexual QOL worsened after treatment, but did not return towards baseline. There were no differences in patient-reported health related QOL as a function of implant interval. Maximum physician-rated GU, GI, and sexual toxicity rates of grade 2 or 3 were 68%, 3%, and 53%, respectively. There was no difference in rates of grade 2 or 3 toxicity as a function of implants interval.

Conclusions: HDR brachytherapy for prostate cancer is a well-tolerated treatment. The interval between treatments is not associated with differences in patient-reported QOL or physician-rated toxicities.

J Contemp Brachytherapy 2020; 12, 3: 216–224
DOI: https://doi.org/10.5114/jcb.2020.96861

Key words: brachytherapy, prostate cancer, implant interval, patient-reported outcomes, quality of life, toxicity.
Material and methods

Study design and patient selection

We performed a retrospective cohort study of a prospectively maintained, Institutional Review Board approved database of patients treated with HDR brachytherapy for prostate cancer at our institution. All patients provided informed consent prior to participating. We selected patients with NCCN low- or intermediate-risk prostate cancer, undergoing definitive HDR brachytherapy as monotherapy using 13.5 Gy × 2 fractions.

HDR treatment

Our HDR brachytherapy implant procedure and treatment planning details have been previously described [12]. In brief, patients were implanted with between 17 and 22 catheters based on gland size under transrectal ultrasound guidance. After implantation, computed tomography (CT) and, when possible, magnetic resonance imaging (MRI) of the prostate were obtained and registered for target delineation. The prostate was segmented, and an asymmetric planning target volume of 0-5 mm was created and extended to encompass the proximal seminal vesicles. The second fraction was given one to two weeks after the initial treatment, based on patient, physician, and operating room availability. No patients received supplemental external beam radiation or androgen deprivation therapy.

Patient-reported health-related QOL and physician-graded toxicity assessment

Patient-reported genitourinary (GU), gastrointestinal (GI), and sexual QOL were assessed using the international prostate symptom score (IPSS) and the expanded prostate cancer index composite short form (EPIC-26) [13,14]. Baseline patient-reported health-related QOL scores in the GU, GI, and sexual domains were obtained prior to each patient’s first HDR treatment. Patient-reported health-related QOL scores were assessed at each of the patient’s follow-up appointments. Follow-up appointments typically occurred at 1 month, 3 months, 6 months, 12 months, and subsequent 6-month intervals after the second HDR treatment. For the first 39 patients, only IPSS evaluations were used to assess patient-reported QOL. For the subsequent patients, both IPSS and EPIC-26 GU, GI, and sexual function questionnaires were used to assess patient-reported health-related QOL.

Physician-graded toxicity was assessed utilizing common terminology criteria for adverse events (CTCAE) v5.0 criteria [15]. Physician-graded toxicity was assessed at each follow-up visit and reported as the highest grade reported during any follow-up examination.

Minimal clinically important differences

To further evaluate the patient-reported health-related QOL, we characterized statistically significant differences in IPSS or EPIC-26 scores over time or between groups as clinically important or not clinically important through the use of previously reported minimal clinical-

ly important difference (MCID) assessments [16,17,18]. For the IPSS, we utilized previously reported data that showed that a change of 3.0 points represents a slight clinical change, a change of 5.1 points indicating a moderate change, and a change of 8.8 points representing a marked change [17]. For the EPIC-26 scores, we utilized previously reported data with 6-9 points for urinary incontinence score, 5-7 points for urinary obstruction score, 4-6 points for bowel score, and 10-12 points for sexual score, to represent a MCID [18].

Exposure and outcome variables of interest

Implant interval was calculated as the time between the first and second implant and was categorized into two groups: one-week (≤ 10 calendar days apart) or two-weeks (> 10 calendar days apart). The two-week cohort had a higher mean PSA than the one-week cohort (8.02 vs. 6.46, p = 0.04). There were no other differences in the baseline demographic or oncologic variables between the two groups. Chi-square analysis was applied to compare patients based on T-stage, PSA group, Gleason group, and NCCN risk group. Patient-reported health-related QOL and physician-graded toxicities were compared between the two groups using two sample t-tests and generalized linear mixed effects models. Effects were deemed statistically significant with a p < 0.05. If a statistically significant difference was found at any time point between the two groups, an additional evaluation was done to see whether the numerical difference in the assessment leads to a MCID as described above.

Results

One hundred and twenty-two patients were included in the study. The median follow-up was 18 months (range, 1-43 months). The one-week cohort consisted of 63 patients, who were treated with a median of 7 days between implants (range, 5-9). The two-week cohort consisted of 59 patients, who were treated with a median of 14 days between implants (range, 12-28). At baseline, the two-week cohort had a higher mean PSA than the one-week cohort (8.02 vs. 6.46, p = 0.004) and had a higher rate of patients with PSA of 10-20 (34% vs. 13%, p = 0.04). There were no other differences in the baseline demographic or oncologic variables between the two cohorts. The demographic and oncologic specifics of the treated population and the two treatment cohorts are outlined in Table 1.

Patient-reported GU QOL

For the treated population, there was a significant increase in IPSS with reciprocal decline in EPIC-26
urinary incontinence and EPIC-26 urinary obstruction QOL scores from baseline over time. These GU QOL scores displayed a gradual return towards baseline over time. The increase in IPSS at the initial, 1-month assessment constituted a moderate MCID. The increases in IPSS at the 3- and 6-month assessments met the criteria for slight MCID. The increase in IPSS above baseline at the 12-, 18-, and 24-month assessments did not meet criteria for a MCID. The decrease in EPIC-26 urinary incontinence scores at the 1-, 3-, 12-, and 18-month assessments were found to be MCID, while the differences at the 6- and 24-month assessments did not meet MCID criteria. EPIC-26 urinary obstruction scores at the 1- and 3-month assessments both met MCID criteria.

There were no differences in mean baseline IPSS or EPIC-26 urinary incontinence scores at any individual follow-up assessments. At the 12-month follow-up visit, the mean EPIC-26 urinary obstruction QOL score in the two-week cohort was lower as compared with the one-week cohort, with the difference meeting MCID criteria (78.9 vs. 87.5, \( p = 0.04 \)). This difference was eliminated at subsequent evaluations. The comparison in patient-reported GU toxicities between the two cohorts are presented in Table 3 and Figure 2A-C.

### Patient-reported GI QOL

For the treated population, there was a significant decrease in the EPIC-26 bowel QOL scores at the 1- and 3-month follow-up assessments, as compared with baseline. Only the decrease seen at the 1-month assessment met criteria for MCID. Over time, the EPIC-26 bowel QOL scores returned to baseline. The EPIC-26 bowel scores for the whole cohort are shown in Table 2 and Figure 1.

There were no differences in mean baseline IPSS, EPIC-26 urinary incontinence QOL, or EPIC-26 urinary obstruction QOL scores between the one-week and two-week cohorts. Over time, there were no significant differences in IPSS (\( p = 0.121 \)), EPIC-26 urinary incontinence scores (\( p = 0.732 \)), or EPIC-26 urinary obstruction scores (\( p = 0.963 \)) between the one-week and two-week cohorts.

### Table 1. Patient baseline demographic and oncologic specifics

|                         | Treated population | One-week cohort | Two-week cohort | \( P \)-value |
|-------------------------|--------------------|-----------------|----------------|--------------|
| Number                  | 122                | 63              | 59             | –            |
| Days between implants, median (range) | 9 (5-28)         | 7 (5-9)         | 14 (12-28)    | –            |
| Age (years), median (range) | 67.5 (47-78)     | 67 (47-78)      | 68 (50-78)    | 0.946        |
| Gland size, median (range) | 36 (14.5-91.9)  | 35 (14.5-81)    | 37 (18.8-91)  | 0.209        |
| PSA, median (range)      | 6.42 (0.52-16.4)  | 5.74 (1.2-14.2) | 6.93 (0.52-16.4) | 0.004 |
| PSA group, \( n \) (%)   |                    |                 |                | 0.04         |
| PSA < 10                 | 100 (82%)          | 56 (90%)        | 44 (75%)      |              |
| 10 \( \geq \) PSA \leq 20 | 22 (18%)          | 7 (10%)         | 15 (25%)      |              |
| T-stage, \( n \) (%)     |                    |                 |                | 0.667        |
| T1c                      | 95 (78%)           | 51 (81%)        | 44 (75%)      |              |
| T2a                      | 22 (18%)           | 10 (16%)        | 12 (20%)      |              |
| T2b                      | 4 (3%)             | 2 (3%)          | 2 (3%)        |              |
| T2c                      | 1 (1%)             | 0 (0%)          | 1 (2%)        |              |
| Gleason group, \( n \) (%) |                      |                 |                | 0.627        |
| Group 1                  | 36 (30%)           | 21 (33%)        | 15 (25%)      |              |
| Group 2                  | 64 (52%)           | 31 (49%)        | 33 (56%)      |              |
| Group 3                  | 22 (18%)           | 11 (18%)        | 11 (19%)      |              |
| Risk group, \( n \) (%)  |                    |                 |                | 0.195        |
| Low                      | 29 (24%)           | 20 (32%)        | 9 (15%)       |              |
| Favorable intermediate    | 61 (50%)           | 29 (46%)        | 32 (54%)      |              |
| Unfavorable intermediate  | 32 (26%)           | 14 (22%)        | 18 (31%)      |              |
at any individual follow-up assessments. The comparison in EPIC-26 bowel QOL scores between the two cohorts are outlined in Table 3 and Figure 2D.

**Patient-reported sexual QOL**

For the treated population, there was a significant decrease in the EPIC-26 sexual QOL score at all follow-up assessments, as compared to baseline. All the decreases in EPIC-26 sexual QOL scores met criteria for MCID.

Over time, the EPIC-26 sexual QOL scores remained lower than baseline, without a trend back towards baseline. The EPIC-26 sexual QOL scores for the treated population are shown in Table 2 and Figure 1.

There was no difference in mean baseline EPIC-26 sexual QOL scores between the one-week cohort and the two-week cohort. There was no difference over time between the one-week and two-week cohorts ($p = 0.34$) or at any individual follow-up assessments. The comparison

---

**Table 2. Whole cohort of patient-reported QOL outcomes compared to baseline**

| Follow-up assessment | Baseline | 1 month | 3 months | 6 months | 12 months | 18 months | 24 months |
|----------------------|----------|---------|----------|----------|-----------|-----------|-----------|
| **IPSS**             |          |         |          |          |           |           |           |
| Number               | 119      | 88      | 93       | 87       | 74        | 58        | 47        |
| Mean                 | 6.8      | 14.7    | 9.9      | 10.0     | 9.1       | 9.4       | 8.6       |
| 95% CI               | ±0.9     | ±1.6    | ±1.2     | ±1.5     | ±1.4      | ±1.4      | ±2.2      |
| Change               | –        | 7.9     | 3.1      | 3.2      | 2.3       | 2.6       | 1.9       |
| $p$-value            | –        | < 0.001 | < 0.001  | < 0.001  | < 0.001   | < 0.001   | 0.009     |

| **Urinary incontinence** |          |         |          |          |           |           |           |
| Number                | 79       | 66      | 81       | 82       | 71        | 50        | 41        |
| Mean                  | 90.2     | 76.9    | 81.9     | 84.7     | 82.34     | 84.2      | 84.8      |
| 95% CI                | ±3.8     | ±5.3    | ±4.8     | ±4.1     | ±4.10     | ±3.9      | ±5.5      |
| Change                | –        | –13.3   | –8.3     | –5.5     | –7.7      | –6.0      | –5.4      |
| $p$-value             | –        | 0.034   | < 0.001  | < 0.001  | < 0.001   | 0.002     | 0.001     |

| **Urinary obstruction** |          |         |          |          |           |           |           |
| Number                | 80       | 63      | 81       | 81       | 69        | 49        | 40        |
| Mean                  | 87.7     | 66.9    | 80.6     | 84.3     | 83.9      | 83.7      | 85.6      |
| 95% CI                | ±3.4     | ±6.9    | ±4.1     | ±3.5     | ±3.9      | ±4.3      | ±5.1      |
| Change                | –        | –20.8   | –7.1     | –3.4     | –3.8      | –4.0      | –2.1      |
| $p$-value             | –        | < 0.001 | 0.002    | 0.057    | 0.099     | 0.281     | 0.302     |

| **Bowel**             |          |         |          |          |           |           |           |
| Number                | 83       | 66      | 82       | 82       | 71        | 53        | 40        |
| Mean                  | 93.0     | 86.3    | 90.7     | 91.3     | 90.8      | 92.2      | 93.2      |
| 95% CI                | ±3.0     | ±4.4    | ±3.2     | ±3.3     | ±3.9      | ±3.7      | ±4.0      |
| Change                | –        | –6.7    | –2.3     | –1.7     | –2.2      | –0.8      | 0.2       |
| $p$-value             | –        | 0.003   | 0.007    | 0.030    | 0.291     | 0.245     | 0.958     |

| **Sexual**           |          |         |          |          |           |           |           |
| Number               | 80       | 59      | 79       | 79       | 72        | 52        | 40        |
| Mean                 | 51.2     | 21.9    | 24.7     | 23.0     | 27.5      | 36.5      | 26.6      |
| 95% CI               | ±6.5     | ±5.8    | ±5.0     | ±4.9     | ±5.2      | ±6.8      | ±9.0      |
| Change               | –        | –29.3   | –26.6    | –28.3    | –23.7     | –14.8     | –24.6     |
| $p$-value            | –        | < 0.001 | < 0.001  | < 0.001  | < 0.001   | < 0.001   | < 0.001   |
treatment. The interval between high-dose per fraction doses per fraction \[19,20\]. This makes hypofractionated low and treatment-related toxicity are of significant interest method of treating localized prostate cancer. The influ

Physician-graded toxicity and acute urinary retention

The overall and comparative rates of the maximum physician-graded toxicity are presented in Figure 3. The overall rate of grade 2 GU, GI, and sexual physician-graded toxicity was 67%, 3%, and 52%, respectively. There was a single incident of grade 3 GU toxicity and a single incident of grade 3 sexual toxicity. There were no reported grade 3 GI toxicities, and no grade 4 or 5 toxicities were observed. There was no difference in the rates of GU \(p = 0.586\), GI \(p = 0.769\), or sexual \(p = 0.177\) physician-graded toxicities between the one-week and two-week cohorts. There were six total incidents of acute urinary retention, for a rate of 5%. Five of the six cases occurred in the one-week cohort; however, this difference was not statistically significant \(p = 0.111\).

Discussion

We performed a retrospective cohort study of patients with low- and intermediate-risk prostate cancer, undergoing definitive HDR prostate brachytherapy with 27 Gy in two fractions. We aimed to compare patient-reported health-related QOL and physician-graded toxicity as a function of time interval between implants. Patients were dichotomized into one-week and two-week cohorts. We found no differences in patient-reported health-related QOL scores or in physician-graded toxicity rates between the one-week and two-week cohorts. This suggests that clinicians should not be concerned about toxicity when planning implant dates using a two-implant regimen.

HDR brachytherapy is a well-studied and widely used method of treating localized prostate cancer. The influence of timing of treatments on prostate cancer outcomes and treatment-related toxicity are of significant interest to brachytherapists. Prostate carcinomas have a relatively low \(\alpha/\beta\) ratio and are therefore more sensitive to large doses per fraction \[19,20\]. This makes hypofractionated HDR brachytherapy a great choice for prostate cancer treatment. The interval between high-dose per fraction treatments can also affect the balance between oncologic outcomes and treatment-related toxicity. Longer overall treatment time has been associated with poor oncologic outcomes, likely due to tumor repopulation and proliferation of radioresistant tumor clonogens \[21,22,23,24\]. However, excessively short treatment duration is associated with increased toxicity, likely due to inadequate recovery of normal tissue \[25,26\].

Various hypofractionated regimens have been compared to evaluate the balance between oncologic outcomes and treatment-related toxicity \[4,5,6,7,8\]. One of the most studied regimens include 27 Gy in two 13.5 Gy fractions, given in two implants, as outlined in the current NCCN guidelines \[10\]. Many studies have outlined their institutional patient-reported QOL and physician-graded toxicity results utilizing this treatment regimen. In a series similar to our dataset, Gaudet et al. reported on their single institutional results of treating thirty low- or intermediate-risk prostate cancer patients with 27 Gy over two implants, separated by 7-14 days \[27\]. They collected patient-reported health-related QOL results utilizing the IPSS and EPIC questionnaires and found 57% of patients treated experienced moderate to severe urinary symptoms at the one-month assessment after implantation, with a rapid recovery towards baseline over time. In contrast, GI symptoms did not change from baseline, while sexual symptoms decreased after implantation, and failed to return to baseline.

Morton et al. reported their results of patients undergoing HDR brachytherapy treatment with 19 Gy in a single fraction or 27 Gy over two fractions, given over two implants. Patients that received the two-implant treatment course received their second implant one week after the first implant. They noted that over the first year, a significant decrease was observed in the mean EPIC urinary and sexual QOL scores over time, with no significant change in the bowel or hormonal QOL scores. For their physician-graded toxicity, they reported that grade 2 urinary toxicity occurred in 51% of patients within the first 3 months and in 31% thereafter. Ten patients (6%) developed urinary retention, and less than 1% had any grade 2 GI toxicity \[8\]. Jawad et al. reported on physician-graded toxicities in treating men with one of three HDR regimens: 38 Gy in 4 fractions, 24 Gy in 2 fractions, or 27 Gy in 2 fractions. Patients who received the two-implant course received their second implant two weeks after the first. They reported grade 1 and 2 dysuria rates of 23% and 6%, and 16% and 7% of grade 1 and 2 urinary retention, with very low rates of acute GI toxicity \[7\].

Our results reflect the above experiences, with similar rates of patient-reported health-related QOL scores and physician-graded toxicities. Patients reported comparable rates of decline in GU, GI, and sexual QOL after treatment. The patient-reported GU and GI QOL scores worsened immediately after treatment, with a return towards baseline over time. However, the patient-reported sexual QOL dropped after treatment and did not trend towards a return to baseline. Our data shows maximum physician-graded toxicity rates of 20%, 67%, and 1% of grade 1, 2, and 3 GU toxicities, respectively. This is likely due in part to our prophylactic use of tamsulosin. Patients, who continued tamsulosin after the implant out
## Table 3. Comparison of patient-reported QOL over time between one-week and two-week cohorts

| Follow-up assessment | Baseline | 1 month | 3 months | 6 months | 12 months | 18 months | 24 months |
|---------------------|----------|---------|----------|----------|-----------|-----------|-----------|
| **IPSS**            |          |         |          |          |           |           |           |
| One-week            | Number   | 63      | 46       | 48       | 44        | 42        | 30        | 22        |
| Mean                |          | 6.2     | 14.0     | 9.4      | 9.5       | 7.9       | 9.0       | 7.4       |
| 95% CI              | ±1.3     | ±2.1    | ±1.5     | ±2.0     | ±1.9      | ±1.8      | ±3.0      |           |
| Two-week            | Number   | 56      | 42       | 45       | 43        | 32        | 28        | 25        |
| Mean                |          | 7.5     | 15.4     | 10.4     | 10.4      | 10.7      | 9.8       | 9.7       |
| 95% CI              | ±1.3     | ±2.5    | ±1.9     | ±2.2     | ±2.2      | ±2.3      | ±3.2      |           |
| Difference           |          | 1.3     | 1.4      | 1.0      | 0.9       | 2.8       | 0.8       | 2.3       |
| *p*-value           |          | 0.167   | 0.405    | 0.429    | 0.535     | 0.056     | 0.597     | 0.288     |
| **Urinary incontinence** |        |         |          |          |           |           |           |
| One-week            | Number   | 45      | 36       | 44       | 43        | 41        | 27        | 21        |
| Mean                |          | 88.0    | 76.2     | 84.2     | 83.4      | 83.6      | 81.7      | 89.4      |
| 95% CI              | ±7.0     | ±7.8    | ±5.9     | ±5.7     | ±5.6      | ±5.4      | ±6.6      |           |
| Two-week            | Number   | 34      | 30       | 37       | 39        | 39        | 30        | 23        |
| Mean                |          | 93.0    | 77.7     | 79.2     | 86.0      | 80.9      | 87.1      | 80.0      |
| 95% CI              | ±4.0     | ±7.6    | ±8.0     | ±7.6     | ±6.1      | ±7.6      | ±6.0      | ±9.0      |
| Difference           |          | 5.1     | 1.5      | 5.0      | 2.6       | 2.6       | 5.4       | 9.5       |
| *p*-value           |          | 0.165   | 0.775    | 0.312    | 0.537     | 0.576     | 0.183     | 0.091     |
| **Urinary obstruction** |        |         |          |          |           |           |           |
| One-week            | Number   | 46      | 35       | 43       | 42        | 40        | 26        | 19        |
| Mean                |          | 88.3    | 67.1     | 81.1     | 83.2      | 87.5      | 85.8      | 86.2      |
| 95% CI              | ±3.7     | ±9.0    | ±5.6     | ±5.6     | ±4.2      | ±4.4      | ±7.9      |           |
| Two-week            | Number   | 34      | 28       | 38       | 39        | 29        | 23        | 21        |
| Mean                |          | 86.8    | 66.5     | 79.9     | 85.4      | 78.9      | 81.3      | 85.1      |
| 95% CI              | ±6.6     | ±11.4   | ±6.3     | ±4.4     | ±4.6      | ±8.0      | ±7.3      |           |
| Difference           |          | 1.6     | 0.6      | 1.2      | 2.2       | 8.6       | 4.6       | 1.1       |
| *p*-value           |          | 0.677   | 0.931    | 0.781    | 0.529     | 0.041     | 0.313     | 0.839     |
| **Bowel**           |          |         |          |          |           |           |           |
| One-week            | Number   | 46      | 35       | 44       | 42        | 40        | 27        | 20        |
| Mean                |          | 91.8    | 84.6     | 89.3     | 88.2      | 91.8      | 91.8      | 93.5      |
| 95% CI              | ±4.1     | ±6.9    | ±4.8     | ±5.3     | ±4.5      | ±4.9      | ±6.2      |           |
| Two-week            | Number   | 37      | 31       | 38       | 40        | 31        | 26        | 20        |
| Mean                |          | 94.5    | 88.2     | 92.4     | 94.5      | 89.6      | 92.6      | 92.9      |
| 95% CI              | ±4.7     | ±5.9    | ±4.3     | ±3.8     | ±6.9      | ±5.9      | ±5.5      |           |
| Difference           |          | 2.7     | 3.5      | 3.1      | 6.3       | 2.2       | 0.8       | 0.6       |
| *p*-value           |          | 0.393   | 0.430    | 0.336    | 0.059     | 0.593     | 0.830     | 0.877     |
| **Sexual**          |          |         |          |          |           |           |           |
| One-week            | Number   | 44      | 31       | 42       | 41        | 39        | 26        | 19        |
| Mean                |          | 50.0    | 25.3     | 26.4     | 23.8      | 29.1      | 40.2      | 30.7      |
| 95% CI              | ±8.6     | ±8.9    | ±7.6     | ±7.5     | ±6.5      | ±9.8      | ±13.6     |           |
| Two-week            | Number   | 39      | 28       | 37       | 38        | 31        | 26        | 21        |
| Mean                |          | 52.8    | 18.1     | 22.7     | 22.1      | 26.6      | 32.7      | 22.9      |
| 95% CI              | ±10.4    | ±7.5    | ±6.6     | ±6.6     | ±9.2      | ±9.8      | ±12.9     |           |
| Difference           |          | 2.8     | 7.2      | 3.7      | 1.7       | 2.4       | 7.5       | 7.8       |
| *p*-value           |          | 0.678   | 0.214    | 0.504    | 0.732     | 0.663     | 0.274     | 0.396     |
Fig. 2. Differences in patient-reported QOL over time between the one-week and two-week cohorts.

Fig. 3. Rates of maximum physician-graded toxicity.

of preference were technically grade 2 based on CTCAE v5.0 criteria. The GI and sexual toxicity were substantially lower with 16% and 3% of grade 1 and grade 2 bowel toxicity, with no grade 3 events, and 15%, 52%, and 1% of grade 1, 2, and 3 sexual toxicity, respectively. Importantly, our results showed that there was no significant difference in any patient-reported health-related QOL or physician-graded toxicity as a function of time between the patients’ first and second treatment. The only statistically significant difference occurred in the EPIC-26 urinary obstruction score at 12 months. This difference was considered as a statistical anomaly, and bears no clinical significance, as the difference was eliminated in all subsequent patient-reported evaluations.

To the authors’ knowledge, there are no other studies that explored the relationship between brachytherapy
Implant interval and outcomes. Our study showed that implant interval did not influence treatment-related toxicity. The next steps in this research is to assess the oncologic outcomes as a function of implant interval. At the time of this study, our data was too immature to perform biochemical control or overall survival analyses. However, Soatti et al. has shown excellent biochemical control and overall survival in a similar population treated with HDR brachytherapy as monotherapy for prostate cancer [28,29]. We plan to calculate these clinical endpoints from our data after longer follow-up.

This study has inherent limitations due to the retrospective study design and its single institution nature. Thus, the risk of selection bias exists. Additionally, unique aspects of our patient’s population and treatment delivery may confound the relationship between implant interval and outcomes.

Conclusions
Our study supports the current body of literature showing that HDR brachytherapy consisting of two implants is a well-tolerated treatment for men with localized prostate cancer. It also indicates that there is no significant difference in the rates of patient-reported health-related QOL or physician-graded toxicity in patients as a function of time between each treatment.

Disclosure
The authors report no conflict of interest.

References
1. Chen RC, Basak R, Meyer AM et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 2017; 317: 1141-1150.
2. Yoshioka Y, Konishi K, Sumida I et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of a prospective study with 50 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011; 80: 469-475.
3. Yoshioka Y, Konishi K, Oh RJ et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006; 80: 62-68.
4. Mavroidis P, Milickovic N, Cruz WF et al. Comparison of different fractionation schemes toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models. Int J Radiat Oncol Biol Phys 2014; 88: 216-223.
5. Hoskin P, Rojas A, Ostler P et al. High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. Radiother Oncol 2014; 112: 63-67.
6. Hoskin P, Rojas A, Ostler P et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity. Radiother Oncol 2014; 110: 268-271.
7. Jawad MS, Dilworth JT, Gustafson GS et al. Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2016; 94: 657-666.
8. Morton G, Chung HT, McGuiffin M et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediately risk prostate cancer: Early toxicity and quality-of-life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 2017; 122: 87-92.
9. Hauswold H, Kamrava MR, Fallon JM et al. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys 2016; 94: 667-674.
10. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2019). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed July 10, 2019.
11. Comparison of HDR vs. LDR brachytherapy as monotherapy for intermediate risk prostate cancer – full text view. ClinicalTrials.gov, clinicaltrials.gov/c트/show/NCT02692105.
12. Solanki AA, Myzs ML, Patel R et al. Transitioning from a low-dose-rate to a high-dose-rate prostate brachytherapy program: comparing initial dosimetry and improving workflow efficiency through targeted interventions. Adv Radiat Oncol 2019; 4:103-111.
13. Barry MJ, Fowler FJ, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557.
14. Wei JT, Dunn RL, Litwin MS et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905.
15. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0: Published: May 28, 2009 (v4.03: June 14, 2010) U.S. Department of Health and Human Services. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
16. Mciothlin AE, Lewis RJ. Minimal clinically important difference: Defining what really matters to patients. JAMA 2014; 312: 1342-1343.
17. Barry MJ, Williford KO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients? J Urol 1995; 154: 1770-1774.
18. Skolarus TA, Dunn RL, Sanda MG et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology 2015; 85: 101-105.
19. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy: an important cause of treatment failure. Int J Radiat Oncol Biol Phys 1992; 23: 1988; 27: 131-146.
20. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001; 50: 1021-1031.
21. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 1275-1288.
22. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23: 457-467.
23. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5: 516-525.
24. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
25. King CR, Brooks JD, Gill H. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048.
26. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment related morbidity after CHART or conventional radiotherapy in head and neck cancer. *Radiother Oncol* 1999; 53: 219-226.

27. Gaudet M, Pharand-Charbonneau M, Desrosiers MP et al. Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer. *Brachytherapy* 2018; 17: 524-529.

28. Soatti CP, Delishaj D, Frigerio C et al. A 13 year experience of prostate HDR brachytherapy: analysis of outcome and toxicity. Abstracts of the 29th Annual Meeting of the Italian Society of Uro-Oncology (SIUrO). *Anticancer Res* 2019; 39: 1507-1629.

29. Soatti CP, Delishaj D, Frigerio C et al. Clinical outcomes and prognostic factors in patients affected by localized prostate cancer treated with HDR brachytherapy. Abstracts of the 29th Annual Meeting of the Italian Society of Uro-Oncology (SIUrO). *Anticancer Res* 2019; 39: 1507-1629.